Identification of Dietary Bioflavonoids as Potential Inhibitors against KRAS G12D Mutant—Novel Insights from Computer-Aided Drug Discovery
Current Issues in Molecular Biology · 06.03.2023 · 45 (3) · 2136-2156
DOI: 10.3390/cimb45030137 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Issues in Molecular Biology, online erschienen am 06.03.2023. Verfasst von Prasanna Srinivasan Ramalingam und 5 weiteren Autor:innen. Beteiligte Einrichtung: Protein Engineering Lab, School of Biosciences and Technology, VIT University, Vellore 632014, Tamil Nadu, India. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The KRAS G12D mutation is very frequent in many cancers, such as pancreatic, colon and lung, and has remained undruggable for the past three decades, due to its smooth surface and lack of suitable pockets. Recent small pieces of evidence suggest that targeting the switch I/II of KRAS G12D mutant could be an efficient strategy. Therefore, in the present study, we targeted the switch I (residues 25–40) and switch II (residues 57–76) regions of KRAS G12D with dietary bioflavonoids in comparison with the reference KRAS SI/II inhibitor BI-2852. Initially, we screened 925 bioflavonoids based on drug-likeness properties, and ADME properties and selected 514 bioflavonoids for further studies. Molecular docking resulted in four lead bioflavonoids, namely 5-Dehydroxyparatocarpin K (L1), Carpachromene (L2), Sanggenone H (L3), and Kuwanol C (L4) with binding affinities of 8.8 Kcal/mol, 8.64 Kcal/mol, 8.62 Kcal/mol, and 8.58 Kcal/mol, respectively, in comparison with BI-2852 (−8.59 Kcal/mol). Further steered-molecular dynamics, molecular-dynamics simulation, toxicity, and in silico cancer-cell-line cytotoxicity predictions significantly support these four lead bioflavonoids as potential inhibitors of KRAS G12D SI/SII inhibitors. We finally conclude that these four bioflavonoids have potential inhibitory activity against the KRAS G12D mutant, and are further to be studied in vitro and in vivo, to evaluate their therapeutic potential and the utility of these compounds against KRAS G12D mutated cancers.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Protein Engineering Lab, School of Biosciences and Technology, VIT University, Vellore 632014, Tamil Nadu, India.
- TanBio R and D Solution, Thanjavur 613403, Tamil Nadu, India.
- Department of Bioinformatics, School of Chemical and Biotechnology, SASTRA Deemed University, Thanjavur 613401, Tamil Nadu, India.
- Quantitative Biology Lab, School of Biosciences and Technology, VIT University, Vellore 632014, Tamil Nadu, India.
ORCID-Profile: Prasanna Srinivasan Ramalingam, Sivakumar Arumugam
Zitieren
APA
Ramalingam, P. S., Balakrishnan, P., Rajendran, S., Jothi, A., Ramalingam, R., & Arumugam, S. (2023). Identification of Dietary Bioflavonoids as Potential Inhibitors against KRAS G12D Mutant—Novel Insights from Computer-Aided Drug Discovery. Current Issues in Molecular Biology, 45(3), 2136-2156. https://doi.org/10.3390/cimb45030137
Vancouver
Ramalingam PS, Balakrishnan P, Rajendran S, Jothi A, Ramalingam R, Arumugam S. Identification of Dietary Bioflavonoids as Potential Inhibitors against KRAS G12D Mutant—Novel Insights from Computer-Aided Drug Discovery. Current Issues in Molecular Biology. 2023;45(3):2136-2156. doi:10.3390/cimb45030137
BibTeX
@article{Ramalingam2023,
author = {Ramalingam, Prasanna Srinivasan and Balakrishnan, Purushothaman and Rajendran, Senthilnathan and Jothi, Arunachalam and Ramalingam, Rajasekaran and Arumugam, Sivakumar},
title = {Identification of Dietary Bioflavonoids as Potential Inhibitors against KRAS G12D Mutant—Novel Insights from Computer-Aided Drug Discovery},
journal = {Current Issues in Molecular Biology},
year = {2023},
volume = {45},
number = {3},
pages = {2136--2156},
doi = {10.3390/cimb45030137}
}
EUVIMED